Evidence map›Paper›PMID 38468504›Full record

ArticleClinical and translational medicine2024

SAA1 and metabolomic signatures predict hyperprogression with immunotherapy in pan cancers.

Xiaoqing Wang, Longshan Zhang, Liwei Liao, Nan Li, Tingxi Tang, Jianda Sun, Zhenhua Zhou, Yang Liu, Jihong Huang, Yingqiao Wang and 9 more

Open access · goldAbstract readLetter
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical and translational medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed, 1 pooled it
0.6field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 synthesis or guideline pooled it, 2 citations in OpenAlex.

  1. Pooled it
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors at 4 institutions in 1 country.

Xiaoqing WangDepartment of Radiation Oncology, Nanfang Hospital, Southern Medical University, Guangzhou, China.
Longshan ZhangDepartment of Radiation Oncology, Nanfang Hospital, Southern Medical University, Guangzhou, China.
Liwei LiaoDepartment of Radiation Oncology, Nanfang Hospital, Southern Medical University, Guangzhou, China.
Nan LiDepartment of Radiation Oncology, Nanfang Hospital, Southern Medical University, Guangzhou, China.
Tingxi TangDepartment of Radiation Oncology, Nanfang Hospital, Southern Medical University, Guangzhou, China.
Jianda SunDepartment of Radiation Oncology, Nanfang Hospital, Southern Medical University, Guangzhou, China.
Zhenhua ZhouDepartment of Respiratory and Critical Care Medicine, Chronic Airways Diseases Laboratory, Nanfang Hospital, Southern Medical University, Guangzhou, China.
Yang LiuSun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangzhou, China.
Jihong HuangDepartment of Respiratory and Critical Care Medicine, Chronic Airways Diseases Laboratory, Nanfang Hospital, Southern Medical University, Guangzhou, China.
Yingqiao WangDepartment of Radiation Oncology, Nanfang Hospital, Southern Medical University, Guangzhou, China.
Zekai ChenDepartment of Radiation Oncology, Nanfang Hospital, Southern Medical University, Guangzhou, China.
Hanbin ZhangDepartment of Radiation Oncology, Nanfang Hospital, Southern Medical University, Guangzhou, China.ORCID 0000-0001-8600-7999
Ting XiaoDepartment of Radiation Oncology, Nanfang Hospital, Southern Medical University, Guangzhou, China.
Yunming TianDepartment of Radiation Oncology, Nanfang Hospital, Southern Medical University, Guangzhou, China.
Xiuting ZhengDepartment of Radiation Oncology, Nanfang Hospital, Southern Medical University, Guangzhou, China.
Yi YuanDepartment of Radiation Oncology, Nanfang Hospital, Southern Medical University, Guangzhou, China.
Linlin XiaoDepartment of Radiation Oncology, Nanfang Hospital, Southern Medical University, Guangzhou, China.
Laiyu LiuDepartment of Respiratory and Critical Care Medicine, Chronic Airways Diseases Laboratory, Nanfang Hospital, Southern Medical University, Guangzhou, China.
Jian GuanDepartment of Radiation Oncology, Nanfang Hospital, Southern Medical University, Guangzhou, China.ORCID 0000-0002-1913-1460
Nanfang Hospital · CNKey Laboratory of Guangdong Province · CNMeizhou City People's Hospital · CNSun Yat-sen University · CN

Funding

Clinical Research Program of Nanfang Hospital, Southern Medical University 2018CR021Clinical Research Program of Nanfang Hospital, Southern Medical University 2020CR025Clinical Research Startup Program of Southern Medical University by High-level University Construction Funding of Guangdong Provincial Department of Education LC2016PY015Clinical Research Startup Program of Southern Medical University by High-level University Construction Funding of Guangdong Provincial Department of Education LC2019ZD008Medical Scientific Research Foundation of Guangdong Province B2021449National Natural Science Foundation of China 822 72729National Natural Science Foundation of China 82303684Natural Science Foundation of Guangdong Province 2022A1515010509Natural Science Foundation of Guangdong Province 2023A1515010285
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

NeoplasmsDisease ProgressionHumansImmunotherapySerum Amyloid A ProteinSAA1 protein, humanSerum Amyloid A Protein

Identifiers

PMID38468504
PMCPMC10928447
OpenAlexW4392714736

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.